InvestorsHub Logo
Followers 23
Posts 4995
Boards Moderated 0
Alias Born 11/01/2006

Re: learning curve post# 12800

Thursday, 02/22/2018 6:45:56 AM

Thursday, February 22, 2018 6:45:56 AM

Post# of 43747
No equation needed. Around 350 +/- patients were enrolled in the last 12 months of the study (2016). With NO Multikine their expected survival would make those patients "events" well into 2019-2020. WITH Multikine I would hope it would be longer.

The study will report if the treatment works and prolongs life and quality of life.

The arb case has nothing to do with the effectiveness of the study but relates to issues with the former CRO.

This is not an assumption but a fact. YOU can assume anything you want but, in my opinion, the approval of Multikine will not happen well into 2019 or early 2020. The arb decision will be reported well before that.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News